Submitted by Anonymous (not verified) on 20 November 2023 - 10:23
Human medicines European public assessment report (EPAR): Gazyvaro, obinutuzumab, Leukemia, Lymphocytic, Chronic, B-Cell, Date of authorisation: 22/07/2014, Revision: 16, Status: Authorised
Source: